|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
® by the SEC on 7/8/20.As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/20 Bionik Laboratories Corp. 10-K® 3/31/20 80:6.6M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 690K
2: EX-4.6 Instrument Defining the Rights of Security Holders HTML 27K
4: EX-10.18 Material Contract HTML 26K
3: EX-10.8 Material Contract HTML 24K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
15: R1 Document And Entity Information HTML 58K
16: R2 Consolidated Balance Sheets HTML 93K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
18: R4 Consolidated Statements of Operations and HTML 79K
Comprehensive Loss
19: R5 Consolidated Statements of Changes in HTML 68K
Shareholders' Equity
20: R6 Consolidated Statements of Cash Flows HTML 111K
21: R7 Nature of Operations and Going Concern HTML 37K
22: R8 Basis of Presentation HTML 28K
23: R9 Significant Accounting Policies HTML 73K
24: R10 Technology and Other Assets HTML 80K
25: R11 Prepaid Expenses and Other Receivables HTML 40K
26: R12 Inventories HTML 34K
27: R13 Equipment HTML 78K
28: R14 Notes Payable HTML 45K
29: R15 Related Party Transactions and Balances HTML 28K
30: R16 Share Capital HTML 83K
31: R17 Stock Options HTML 223K
32: R18 Warrants HTML 70K
33: R19 Income Taxes HTML 84K
34: R20 Risk Management HTML 26K
35: R21 Commitments and Contingencies HTML 34K
36: R22 Subsequent Events HTML 27K
37: R23 Significant Accounting Policies (Policies) HTML 128K
38: R24 Significant Accounting Policies (Tables) HTML 32K
39: R25 Technology and Other Assets (Tables) HTML 79K
40: R26 Prepaid Expenses and Other Receivables (Tables) HTML 40K
41: R27 Inventories (Tables) HTML 34K
42: R28 Equipment (Tables) HTML 78K
43: R29 Notes Payable (Tables) HTML 33K
44: R30 Share Capital (Tables) HTML 79K
45: R31 Stock Options (Tables) HTML 218K
46: R32 Warrants (Tables) HTML 67K
47: R33 Income Taxes (Tables) HTML 89K
48: R34 Nature of Operations and Going Concern (Details) HTML 51K
49: R35 Basis of Presentation (Details) HTML 27K
50: R36 Significant Accounting Policies (Details) HTML 87K
51: R37 TECHNOLOGY AND OTHER ASSETS - Intangible assets HTML 51K
acquired (Details)
52: R38 TECHNOLOGY AND OTHER ASSETS - Additional HTML 27K
Information (Details)
53: R39 Prepaid Expenses and Other Receivables (Details) HTML 35K
54: R40 INVENTORIES- Schedule of Inventories (Details) HTML 24K
55: R41 INVENTORIES - Additional Information (Details) HTML 24K
56: R42 EQUIPMENT - Schedule of net equipment (Details) HTML 48K
57: R43 EQUIPMENT - Additional Information (Details) HTML 24K
58: R44 NOTES PAYABLE - Conversion of Notes Payable HTML 42K
(Details)
59: R45 Notes Payable (Details) HTML 62K
60: R46 Notes Payable - Short term loan (Details) HTML 34K
61: R47 Related Party Transactions and Balances (Details) HTML 41K
62: R48 SHARE CAPITAL - Common shares issued (Details) HTML 55K
63: R49 SHARE CAPITAL - Additional Information (Details) HTML 85K
64: R50 STOCK OPTION - Black-Scholes Option Pricing Model HTML 96K
(Details)
65: R51 STOCK OPTION - Option Activity (Details) HTML 37K
66: R52 STOCK OPTIONS - Summary of stock options HTML 106K
outstanding and exercisable (Details)
67: R53 STOCK OPTIONS - Additional Information (Details) HTML 139K
68: R54 WARRANTS - Summary of continuity schedule HTML 44K
(Details)
69: R55 WARRANTS - Summary of common share purchase HTML 38K
warrants outstanding (Details)
70: R56 WARRANTS - Additional Information (Details) HTML 61K
71: R57 INCOME TAXES - Schedule of reconciliation of the HTML 53K
us income tax rate (Details)
72: R58 INCOME TAXES - Schedule of deferred tax assets and HTML 44K
liabilities (Details)
73: R59 INCOME TAXES - Income Tax Examination Open Tax HTML 31K
Years (Details)
74: R60 INCOME TAXES - Narrative (Details) HTML 28K
75: R61 Risk Management (Details) HTML 38K
76: R62 Commitments and Contingencies (Details) HTML 49K
77: R63 Subsequent Events (Details) HTML 37K
79: XML IDEA XML File -- Filing Summary XML 137K
78: EXCEL IDEA Workbook of Financial Reports XLSX 101K
9: EX-101.INS XBRL Instance -- bnkl-20200331 XML 2.12M
11: EX-101.CAL XBRL Calculations -- bnkl-20200331_cal XML 139K
12: EX-101.DEF XBRL Definitions -- bnkl-20200331_def XML 547K
13: EX-101.LAB XBRL Labels -- bnkl-20200331_lab XML 1.09M
14: EX-101.PRE XBRL Presentations -- bnkl-20200331_pre XML 900K
10: EX-101.SCH XBRL Schema -- bnkl-20200331 XSD 196K
80: ZIP XBRL Zipped Folder -- 0001104659-20-078067-xbrl Zip 158K
Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Leslie Markow, certify that:
| 1. | I have reviewed this Annual Report on Form 10-K of Bionik Laboratories Corp. |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | ||
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | ||
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | ||
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
| c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and | ||
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): | ||
| a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | ||
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting. | ||
| Date: June 29, 2020 | |
| /s/ Leslie Markow | |
| Leslie Markow | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Changed on / Corrected on: | 7/8/20 | 8-K | ||
| Filed on: | 6/29/20 | |||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/23 Bionik Laboratories Corp. 10-K 3/31/23 78:8.6M Toppan Merrill/FA2 2/08/23 Bionik Laboratories Corp. 10-Q 12/31/22 59:4.8M Toppan Merrill/FA2 11/09/22 Bionik Laboratories Corp. 10-Q 9/30/22 56:4.4M Toppan Merrill/FA2 8/10/22 Bionik Laboratories Corp. 10-Q 6/30/22 48:3.5M Toppan Merrill/FA2 6/09/22 Bionik Laboratories Corp. 10-K 3/31/22 68:7.9M Toppan Merrill/FA2 6/24/21 Bionik Laboratories Corp. 10-K 3/31/21 71:6.3M Toppan Merrill/FA |